Ovarian cancer early detection by circulating CA125 in the context of anti‐CA125 autoantibody levels: Results from the EPIC cohort. Issue 7 (11th December 2017)

• Record Type: Journal Article
• Authors: Fortner, Renée T.; Schock, Helena; Le Cornet, Charlotte; Hüsing, Anika; Vitonis, Allison F.; Johnson, Theron S.; Fichorova, Raina N.; Fashemi, Titilayo; Yamamoto, Hidemi S.; Tjønneland, Anne; Hansen, Louise; Overvad, Kim; Boutron‐Ruault, Marie‐Christine; Kvaskoff, Marina; Severi, Gianluca; Boeing, Heiner; Trichopoulou, Antonia; Papatesta, Eleni‐Maria; La Vecchia, Carlo; Palli, Domenico; Sieri, Sabina; Tumino, Rosario; Sacerdote, Carlotta; Mattiello, Amalia; Onland‐Moret, N. Charlotte; Peeters, Petra H.; Bueno‐de‐Mesquita, H. B(as); Weiderpass, Elisabete; Quirós, J. Ramón; Duell, Eric J.; Sánchez, Maria‐Jose; Navarro, Carmen; Ardanaz, Eva; Larrañaga, Nerea; Nodin, Björn; Jirström, Karin; Idahl, Annika; Lundin, Eva; Khaw, Kay‐Tee; Travis, Ruth C.; Gunter, Marc; Johansson, Mattias; Dossus, Laure; Merritt, Melissa A.; Riboli, Elio; Terry, Kathryn L.; Cramer, Daniel W.; Kaaks, Rudolf;
• Is Part Of: International journal of cancer. Volume 142:Issue 7(2018)
• Page Start: 1355
• Page End: 1360
• Publication Date: 2017-12-11
• Subjects: ovarian cancer -- early detection markers -- CA125 -- anti‐CA125 antibodies -- MUC16 -- autoantibodies; Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.31164
• Languages: English
• ISSNs: 0020-7136

Abstract

Abstract : CA125 is the best ovarian cancer early detection marker to date; however, sensitivity is limited and complementary markers are required to improve discrimination between ovarian cancer cases and non‐cases. Anti‐CA125 autoantibodies are observed in circulation. Our objective was to evaluate whether these antibodies (1) can serve as early detection markers, providing evidence of an immune response to a developing tumor, and (2) modify the discriminatory capacity of CA125 by either masking CA125 levels (resulting in lower discrimination) or acting synergistically to improve discrimination between cases and non‐cases. We investigated these objectives using a nested case–control study within the European Prospective Investigation into Cancer and Nutrition cohort (EPIC) including 250 cases diagnosed within 4 years of blood collection and up to four matched controls. Circulating CA125 antigen and antibody levels were quantified using an electrochemiluminescence assay. Adjusted areas under the curve (aAUCs) by 2‐year lag‐time intervals were calculated using conditional logistic regression calibrated toward the absolute risk estimates from a pre‐existing epidemiological risk model as an offset‐variable. Anti‐CA125 levels alone did not discriminate cases from controls. For cases diagnosed <2 years after blood collection, discrimination by CA125 antigen was suggestively higher with higher anti‐CA125 levels (aAUC, highest antibody tertile: 0.84 [0.76–0.92]; lowest tertile: 0.76 [0.67–0.86]; p het = 0.06). We provide the first evidence of potentially synergistic discrimination effects of CA125 and anti‐CA125 antibodies in ovarian early detection. If these findings are replicated, evaluating CA125 in the context of its antibody may improve ovarian cancer early detection. Abstract : What's new? Although CA125, a mucin produced in epithelial cells, is a known marker for ovarian cancer, complementary biomarkers are necessary for reliable early cancer detection. Here, the authors examined autoantibodies against CA125 as potential pre‐diagnosis markers. Although anti‐CA125 levels did not discriminate between ovarian cases and controls, discrimination of CA125 differed by levels of its antibody, with the highest discrimination among women with the highest antibody levels. The authors propose that CA125 and anti‐CA125 may act synergistically for ovarian cancer early detection.